



MAJOR SHAREHOLDER ANNOUNCEMENT

May 10, 2012

In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has reduced its holding of B shares in Novozymes to 7.71%, previously reported at 7.81% (a decrease of 0.10%).

Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 25,072,500 shares of a nominal value of DKK 50,145,000, equivalent to 7.71% of Novozymes A/S' share capital and 3.10% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, decreasing its holding of B shares in Novozymes A/S to a total of 15,985,952 B shares of a nominal value of DKK 31,971,904, equivalent to 4.92% of Novozymes share capital.

Contact persons:

Press and media:

René Tronborg (Europe)

Tel. (direct): +45 4446 2274

Tel. (mobile): +45 3077 2274

Investor relations:

Martin Riise

Tel. (direct): +45 4446 0738

Tel. (mobile): +45 3077 0738

Paige Donnelly (USA)

Tel. (direct): +1 919 494 3209

Tel. (mobile): +1 919 218 4501

Thomas Bomhoff (USA)

Tel. (direct): +1 919 494 3483

Tel. (mobile): +1 919 649 2565

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.